^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TTX-080

    i
    Other names: TTX-080
    Associations

    News

    Trials
    Company:
    Tizona Therap
    Drug class:
    HLA G inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (clinicaltrials.gov)
    P1, N=240, Active, not recruiting, Tizona Therapeutics, Inc | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • TTX-080
    10ms
    TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (clinicaltrials.gov)
    P1a/1b, N=240, Active, not recruiting, Tizona Therapeutics, Inc | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2023 --> Dec 2023
    Enrollment closed • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • TTX-080